| Literature DB >> 31572976 |
Pei-Yu Chen1, Lingfeng Qin2, Guangxin Li2,3, Zheng Wang4, James E Dahlman5,6,7,8, Jose Malagon-Lopez9,10, Sharvari Gujja9,10, Nicholas A Cilfone9,10, Kevin J Kauffman6, Lele Sun11, Hongye Sun11, Xinbo Zhang12, Binod Aryal12, Alberto Canfran-Duque12, Rebecca Liu13, Pascal Kusters14, Alfica Sehgal15,16, Yang Jiao2, Daniel G Anderson5,6,7,17, Jeffrey Gulcher18, Carlos Fernandez-Hernando12, Esther Lutgens14,19, Martin A Schwartz1, Jordan S Pober13, Thomas W Chittenden9,10,20, George Tellides2, Michael Simons21,22.
Abstract
Atherosclerosis is a progressive vascular disease triggered by interplay between abnormal shear stress and endothelial lipid retention. A combination of these and, potentially, other factors leads to a chronic inflammatory response in the vessel wall, which is thought to be responsible for disease progression characterized by a buildup of atherosclerotic plaques. Yet molecular events responsible for maintenance of plaque inflammation and plaque growth have not been fully defined. Here we show that endothelial TGFβ signaling is one of the primary drivers of atherosclerosis-associated vascular inflammation. Inhibition of endothelial TGFβ signaling in hyperlipidemic mice reduces vessel wall inflammation and vascular permeability and leads to arrest of disease progression and regression of established lesions. These pro-inflammatory effects of endothelial TGFβ signaling are in stark contrast with its effects in other cell types and identify it as an important driver of atherosclerotic plaque growth and show the potential of cell-type specific therapeutic intervention aimed at control of this disease.Entities:
Year: 2019 PMID: 31572976 PMCID: PMC6767930 DOI: 10.1038/s42255-019-0102-3
Source DB: PubMed Journal: Nat Metab ISSN: 2522-5812